Dataset Information

Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems.

ABSTRACT: Over the past few years, nanotechnology has been attracting considerable research attention because of their outstanding mechanical, electromagnetic and optical properties. Nanotechnology is an interdisciplinary field comprising nanomaterials, nanoelectronics, and nanobiotechnology, as three areas which extensively overlap. The application of metal nanoparticles (MNPs) has drawn much attention offering significant advances, especially in the field of medicine by increasing the therapeutic index of drugs through site specificity preventing multidrug resistance and delivering therapeutic agents efficiently. Apart from drug delivery, some other applications of MNPs in medicine are also well known such as in vivo and in vitro diagnostics and production of enhanced biocompatible materials and nutraceuticals. The use of metallic nanoparticles for drug delivery systems has significant advantages, such as increased stability and half-life of drug carrier in circulation, required biodistribution, and passive or active targeting into the required target site. Green synthesis of MNPs is an emerging area in the field of bionanotechnology and provides economic and environmental benefits as an alternative to chemical and physical methods. Therefore, this review aims to provide up-to-date insights on the current challenges and perspectives of MNPs in drug delivery systems. The present review was mainly focused on the greener methods of metallic nanocarrier preparations and its surface modifications, applications of different MNPs like silver, gold, platinum, palladium, copper, zinc oxide, metal sulfide and nanometal organic frameworks in drug delivery systems.

SUBMITTER: Chandrakala V

PROVIDER: S-EPMC8724657 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Alzheimer's disease (AD), the most common form of dementia, is a progressive and multifactorial neurodegenerative disorder whose primary causes are mostly unknown. Due to the increase in life expectancy of world population, including developing countries, AD, whose incidence rises dramatically with age, is at the forefront among neurodegenerative diseases. Moreover, a definitive cure is not yet within reach, imposing substantial medical and public health burdens at every latitude. Therefore, the effort to devise novel and effective therapeutic strategies is still of paramount importance. Genetic, functional, structural and biochemical studies all indicate that new and efficacious drug delivery strategies interfere at different levels with various cellular and molecular targets. Over the last few decades, therapeutic development of nanomedicine at preclinical stage has shown to progress at a fast pace, thus paving the way for its potential impact on human health in improving prevention, diagnosis, and treatment of age-related neurodegenerative disorders, including AD. Clinical translation of nano-based therapeutics, despite current limitations, may present important advantages and innovation to be exploited in the neuroscience field as well. In this state-of-the-art review article, we present the most promising applications of polymeric nanoparticle-mediated drug delivery for bypassing the blood-brain barrier of AD preclinical models and boost pharmacological safety and efficacy. In particular, novel strategic chemical functionalization of polymeric nanocarriers that could be successfully employed for treating AD are thoroughly described. Emphasis is also placed on nanotheranostics as both potential therapeutic and diagnostic tool for targeted treatments. Our review highlights the emerging role of nanomedicine in the management of AD, providing the readers with an overview of the nanostrategies currently available to develop future therapeutic applications against this chronic neurodegenerative disease.

Dataset Information

Review on metal nanoparticles as nanocarriers: current challenges and perspectives in drug delivery systems.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets